APPREZIATE · IM047-066

Observational study conducted in hospitals across Spain to evaluate the persistence of treatment with ozanimod (Zeposia®) in patients with relapsing-remitting multiple sclerosis. The study focuses on treatment-naive patients with low or moderate disease activity levels.

Observational, multicenter study to describe the persistence in relapsing remitting multiple sclerosis naive patients with low-moderate activity treated with Ozanimod (Zeposia ®) in clinical practice in Spain

Sponsor: BMS

Phase: IV

Status: Follow-up

View clinical trials catalogue

Public study eligibility criteria

Inclusion

  • * Relapsing-remitting multiple sclerosis (RRMS) diagnosis by 2017 revised McDonald criteria at the treatment start
  • * Participant who started treatment with ozanimod for the first time 3 months (+/- 2 weeks) before inclusion, according to European Union (EU) Summary of Product Characteristics (SmPC) and/or Spanish therapeutic positioning report (TPR) recommendation and following routine clinical practice of the participating hospital
  • * Low-to-moderate activity, defined as less than 2 relapses in the previous year before starting the treatment with ozanimod

Exclusion

  • * Prior exposure to ozanimod or any other disease modifier treatment (DMT) for RRMS before starting treatment with ozanimod subject of this study
  • * Participant who has started ozanimod within a clinical trial
  • Note: Other protocol-defined inclusion/exclusion criteria apply